A metaregression analysis indicated that , after adjusting for possible confounders , studies where fluoxetine was the experimental agent were positively associated with treatment effect , indicating a significant advantage for fluoxetine .
The evidence that the outcome of fluoxetine trials varied according to whether this drug was used as a new compound or a reference one suggests the presence of bias
The present study investigated whether the outcome of r and omized clinical trials study ing fluoxetine favored fluoxetine , where this was the experimental agent , and favored comparator antidepressants in trials where fluoxetine was the reference agent .
Fluoxetine in depressed patients: a comparison with imipramine.
The clinical efficacy and safety of fluoxetine and imipramine were compared in a double-blind , 5-week , parallel study in 40 depressed out patients .  Mean scores for most depression scales improved more in patients taking fluoxetine than in those receiving imipramine ( p less than .05 ) . Nine of 16 ( 56 % ) fluoxetine patients who completed the study and 1 of 19 ( 5 % ) imipramine patients were not at all depressed at the end of the study ( p less than .001 ) . Seven fluoxetine patients and 14 imipramine patients reported one or more adverse effects during treatment ; no fluoxetine patient terminated the study early for drug-related reasons . It was concluded that fluoxetine provides effective antidepressant activity with fewer and less troublesome side effects than imipramine
A metaregression analysis indicated that , after adjusting for possible confounders , studies where fluoxetine was the experimental agent were positively associated with treatment effect , indicating a significant advantage for fluoxetine .
The evidence that the outcome of fluoxetine trials varied according to whether this drug was used as a new compound or a reference one suggests the presence of bias
The present study investigated whether the outcome of r and omized clinical trials study ing fluoxetine favored fluoxetine , where this was the experimental agent , and favored comparator antidepressants in trials where fluoxetine was the reference agent .